摘要
背景:肽和基于肽的治疗剂是划定重要化学空间的生物分子,可将小分子与生物治疗剂(如抗体、重组蛋白和蛋白质结构域)联系起来。 简介: 环寡肽和缩肽,尤其是蓝藻衍生的噻唑啉基多肽 (CTBC),由于其独特的结构特征和有趣的生物作用,表现出广泛的药理活性,为药物发现提供了有希望的线索。 方法:在本研究中,我们全面回顾了 CTBCs 的天然来源、区分化学成分和相关的生物特征。我们分析了它们的结构特性,计算了生物学描述的作用方式,这使得 CTBCs 成为出现基于肽的前瞻性疗法不可或缺的来源。在这种情况下,还简要讨论了金属有机框架及其生物医学应用。首先,给出了基于肽的疗法的挑战、方法和临床状态。 结果:基于这些分析,CTBC 可以被评估为理想的药物靶点,这对于传统的小分子一直是一个挑战,例如那些参与蛋白质-蛋白质相互作用的小分子,或者将被开发为潜在的癌症靶向纳米材料。这些环寡肽的环化诱导降低的构象自由度有助于改善代谢稳定性和与其分子靶标的结合亲和力。几种环肽的临床成功引发了天然产物样环肽的大型文库筛选和合成,以解决未满足的医疗需求。 结论:CTBCs可以被认为是最有前途的药物发现先导化合物。采用先进的生物和生物制药策略的融合可能会使这些环肽成为未来治疗应用的潜在生物分子。
关键词: 唑啉基肽,蓝藻,噻唑啉,细胞毒性,全合成,SAR,环缩肽。
Current Medicinal Chemistry
Title:Natural Thiazoline-Based Cyclodepsipeptides from Marine Cyanobacteria: Chemistry, Bioefficiency and Clinical Aspects
Volume: 28 Issue: 38
关键词: 唑啉基肽,蓝藻,噻唑啉,细胞毒性,全合成,SAR,环缩肽。
摘要:
Background: Peptides and peptide-based therapeutics are biomolecules that demarcate a significant chemical space to bridge small molecules with biological therapeutics, such as antibodies, recombinant proteins, and protein domains.
Introduction: Cyclooligopeptides and depsipeptides, particularly cyanobacteria-derived thiazoline-based polypeptides (CTBCs), exhibit a wide array of pharmacological activities due to their unique structural features and interesting bioactions, which furnish them as promising leads for drug discovery.
Methods: In the present study, we comprehensively review the natural sources, distinguishing chemistries, and pertinent bioprofiles of CTBCs. We analyze their structural peculiarities counting the mode of actions for biological portrayals which render CTBCs as indispensable sources for emergence of prospective peptide-based therapeutics. In this milieu, metal organic frameworks and their biomedical applications are also briefly discussed. To boot, the challenges, approaches, and clinical status of peptide-based therapeutics are conferred.
Results: Based on these analyses, CTBCs can be appraised as ideal drug targets that have always remained a challenge for traditional small molecules, like those involved in protein- protein interactions or to be developed as potential cancer-targeting nanomaterials. Cyclization-induced reduced conformational freedom of these cyclooligopeptides contribute to improved metabolic stability and binding affinity to their molecular targets. Clinical success of several cyclic peptides provokes the large library-screening and synthesis of natural product-like cyclic peptides to address the unmet medical needs.
Conclusion: CTBCs can be considered as the most promising lead compounds for drug discovery. Adopting the amalgamation of advanced biological and biopharmaceutical strategies might endure these cyclopeptides to be prospective biomolecules for futuristic therapeutic applications in the coming times.
Export Options
About this article
Cite this article as:
Natural Thiazoline-Based Cyclodepsipeptides from Marine Cyanobacteria: Chemistry, Bioefficiency and Clinical Aspects, Current Medicinal Chemistry 2021; 28 (38) . https://dx.doi.org/10.2174/0929867328666210526095436
DOI https://dx.doi.org/10.2174/0929867328666210526095436 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application
Current Medicinal Chemistry Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Estrogen Activates Classical and Alternative Mechanisms to Orchestrate Neuroprotection
Current Neurovascular Research Biology of Circulating Nucleic Acids and Possible Roles in Diagnosis and Treatment in Diabetes and Cancer
Infectious Disorders - Drug Targets Nanomedicine for Cancer Therapy Using Autophagy: An Overview
Current Topics in Medicinal Chemistry Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Clinical Trials: Potential Effects of Inserted Sequences
Current Gene Therapy Part I: Targeted Particles for Cancer Immunotherapy
Current Drug Delivery Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Editorial [Personalized Vaccines and Public Health Genomics: Anticipating and Monitoring the ELSIs]
Current Pharmacogenomics and Personalized Medicine Anti-Cancer Potential of Some Commonly Used Drugs
Current Pharmaceutical Design Synthesis of pyridyl benzimidazoles encompassing 4-thiazolidinone derivatives as potential antimicrobial agents
Letters in Drug Design & Discovery LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Mucoadhesive Polymeric Platform for Drug Delivery; A Comprehensive Review
Current Drug Delivery High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design MicroRNAs in Human Virus Genomes: Helping Hands for Viral Infection
MicroRNA Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine DNA Instability at Chromosomal Fragile Sites in Cancer
Current Genomics